The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Open accessAbstract
HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of four different T-cell clonotypes that specifically targeted KRAS G12D. However, one of these lesions had progressed on evaluation 9 months after therapy. The lesion was resected and found to have lost the chromosome 6 haplotype encoding the HLA-C*08:02 class I major histocompatibility complex (MHC) molecule. The loss of expression of this molecule provided a direct mechanism of tumor immune evasion. Thus, the infusion of CD8+ cells targeting mutant KRAS mediated effective antitumor immunotherapy against a cancer that expressed mutant KRAS G12D and HLA-C*08:02.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This approach has shown efficacy in colon cancer and NSCLC patients with mutant KRAS G12D and HLA-C*08:02 expression [88].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tumors with mutant KRAS can express neoantigen fragments containing the oncogenic driver mutation on the major histocompatibility complex [88,89].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
In the citing paper
“CD8+ TILs and TCRs in CD4+ T cells have been found to specifically recognize KRAS-related mutations, which can be further used to engineer T cells.604,605”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [604]
In the citing paper
“As noted above, peptides derived from KRASG12 variants193,194, and also from KRASQ61H/L/R (ref.198), have been demonstrated to be presented on the surface of malignant cells by various MHC I (HLA-A) molecules.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“ACT with these specific TILs resulted in regression of all seven pulmonary metastases in a patient with KRASG12D-mutant CRC from whom they had been isolated193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Notably, loss of MHC was identified as an immune-evasion mechanism in a tumour that progressed 9 months after TIL infusion193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Endogenous immune responses against KRAS-mutant cancer cells were first described in 2016 by Tran et al.193, who identified CD8+ TILs with T cell receptors (TCRs) that recognize MHC I (HLA-C*08:02)-presented peptide neoepitopes derived from KRASG12D.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Using CD8+ T cells that were reactive to KRASG12D mutant, a patient with CRC experienced prolonged partial response [64].”
From KRAS, a New Target for Precision Medicine in Colorectal Cancer? (2024) · cites this paper as [64]
In the citing paper
“It was found that CD8+ T cells, possessing HLA-C08:02-restricted T-cell receptors, specifically recognize the mutant KRASG12D.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Following the intravenous administration of expanding TCRs in an ex vivo environment, a complete response was observed in lung lesions, resulting in prolonged PFS.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“A recent publication presented the relationship between the KRASG12D mutation and TCRs in a patient diagnosed with metastatic mCRC with lung metastasis [106].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Despite the rarity of HLA-C*08:02, this study demonstrated the promise of T-cell–based immunotherapy for targeting KRASG12D and HLA-C*08:02.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“Tran and colleagues described a case of a patient with metastatic colorectal cancer treated with autologous T cells specific for mutant KRASG12D, which was restricted to the major histocompatibility complex class I allele HLA-C*08:02 (44).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“The anti-tumor activity of ICB has been shown to depend on CD8+ T cell, HLA class I–dependent immune activity (34–36).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,208
Self-citationCancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,737
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625
Self-citationAllele-specific copy number analysis of tumors
Loo, P. V., Nord, S., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,192
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,001–1,002 of 1,002
Research progress of T cells in cholangiocarcinoma
Wang, Z., Dai, Y., Zhou, Y., Wang, Y., Chen, P., Li, Y., Zhang, Y., Wang, X., Hu, Y., Li, H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1453344 · Cited by 2
Sagawa, T., Hirakawa, M., Nagashima, H., & Fujikawa, K. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01579-8 · Cited by 1
Metadata
- Authors
- Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., Kriley, I. R., & Rosenberg, S. A.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-08
- Volume
- 375
- Issue
- 23
- Pages
- 2255-2262
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5178827
- OpenAlex
- W2559953355
- Cited by
- 1,368
- References
- 27
- Citations by year
- 2026: 96 · 2025: 132 · 2024: 129 · 2023: 162 · 2022: 162 · 2021: 183 · 2020: 149 · 2019: 134 · 2018: 118 · 2017: 98 · 2016: 3
- FWCI
- 71.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01BC010984)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- tumor-infiltrating lymphocytes, mutant KRAS, KRAS G12D, CD8+ T cells, tumor immune evasion, MHC class I loss, cancer immunotherapy
- MeSH terms
- Female, Flow Cytometry, Humans, Lung, Lung Neoplasms, Middle Aged, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), CD8-Positive T-Lymphocytes, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
